A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs LY 03005 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Acronyms LY03005SAD
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 09 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 24 Feb 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top